BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S. Rationale for targeting complement in COVID-19. EMBO Mol Med 2020;12:e12642. [PMID: 32559343 DOI: 10.15252/emmm.202012642] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Polycarpou A, Grigoriadou S, Klavinskis L, Sacks S. Does the Lectin Complement Pathway Link Kawasaki Disease and SARS-CoV-2? Front Immunol 2020;11:604512. [PMID: 33584675 DOI: 10.3389/fimmu.2020.604512] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Kircheis R, Planz O. Could a Lower Toll-like Receptor (TLR) and NF-κB Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron? Int J Mol Sci 2022;23:5966. [PMID: 35682644 DOI: 10.3390/ijms23115966] [Reference Citation Analysis]
3 Howard MC, Nauser CL, Farrar CA, Sacks SH. Correction to: Complement in ischaemia-reperfusion injury and transplantation. Semin Immunopathol 2022. [PMID: 35304658 DOI: 10.1007/s00281-022-00924-w] [Reference Citation Analysis]
4 Johri S, Goyal M, Jain S, Baranwal M, Kumar V, Upadhyay R. A novel machine learning‐based analytical framework for automatic detection of COVID ‐19 using chest X‐ray images. Int J Imaging Syst Technol 2021;31:1105-19. [DOI: 10.1002/ima.22613] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Postgrad Med 2021;133:489-507. [PMID: 33245005 DOI: 10.1080/00325481.2020.1855921] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 Mba IE, Sharndama HC, Osondu-Chuka GO, Okeke OP. Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. Infect Dis (Lond) 2021;53:559-80. [PMID: 33905282 DOI: 10.1080/23744235.2021.1916071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Semeraro N, Colucci M. The Prothrombotic State Associated with SARS-CoV-2 Infection: Pathophysiological Aspects. Mediterr J Hematol Infect Dis 2021;13:e2021045. [PMID: 34276914 DOI: 10.4084/MJHID.2021.045] [Reference Citation Analysis]
8 Halawa S, Pullamsetti SS, Bangham CRM, Stenmark KR, Dorfmüller P, Frid MG, Butrous G, Morrell NW, de Jesus Perez VA, Stuart DI, O'Gallagher K, Shah AM, Aguib Y, Yacoub MH. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nat Rev Cardiol 2021. [PMID: 34873286 DOI: 10.1038/s41569-021-00640-2] [Reference Citation Analysis]
9 Synowiec A, Szczepański A, Barreto-Duran E, Lie LK, Pyrc K. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. Clin Microbiol Rev 2021;34:e00133-20. [PMID: 33441314 DOI: 10.1128/CMR.00133-20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
10 Zhang Z. Association of C5a/C5aR pathway to activate ERK1/2 and p38 MAPK in acute kidney injury – a mouse model. Revista Romana de Medicina de Laborator 2022;30:31-40. [DOI: 10.2478/rrlm-2022-0001] [Reference Citation Analysis]
11 Jafarpour R, Pashangzadeh S, Dowran R. Host factors: Implications in immunopathogenesis of COVID-19. Pathol Res Pract 2021;228:153647. [PMID: 34749207 DOI: 10.1016/j.prp.2021.153647] [Reference Citation Analysis]
12 Rodríguez de la Concepción ML, Ainsua-Enrich E, Reynaga E, Ávila-Nieto C, Santos JR, Roure S, Mateu L, Paredes R, Puig J, Jimenez JM, Izquierdo-Useros N, Clotet B, Pedro-Botet ML, Carrillo J. High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients. Life Sci Alliance 2021;4:e202001009. [PMID: 34321327 DOI: 10.26508/lsa.202001009] [Reference Citation Analysis]
13 Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S. Rationale for targeting complement in COVID-19. EMBO Mol Med 2020;12:e12642. [PMID: 32559343 DOI: 10.15252/emmm.202012642] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
14 Grumach AS, Goudouris E, Dortas Junior S, Marcelino FC, Alonso MLO, Martins RO, Arpon MA, Valle SOR. COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2021;9:508-10. [PMID: 33271349 DOI: 10.1016/j.jaip.2020.11.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Fernandes M, Brábek J. COVID-19, corticosteroids and public health: a reappraisal. Public Health 2021;197:48-55. [PMID: 34325124 DOI: 10.1016/j.puhe.2021.05.028] [Reference Citation Analysis]
16 Labarrere CA, Kassab GS. Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. Front Immunol 2021;12:652252. [PMID: 34630377 DOI: 10.3389/fimmu.2021.652252] [Reference Citation Analysis]
17 Howard MC, Nauser CL, Farrar CA, Sacks SH. Complement in ischaemia-reperfusion injury and transplantation. Semin Immunopathol 2021;43:789-97. [PMID: 34757496 DOI: 10.1007/s00281-021-00896-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zarubova J, Zhang X, Hoffman T, Hasani-Sadrabadi MM, Li S. Biomaterial-based immunoengineering to fight COVID-19 and infectious diseases. Matter 2021;4:1528-54. [PMID: 33723531 DOI: 10.1016/j.matt.2021.02.025] [Reference Citation Analysis]
19 Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One 2021;16:e0261113. [PMID: 34928990 DOI: 10.1371/journal.pone.0261113] [Reference Citation Analysis]
20 Peerschke EI, Valentino A, So RJ, Shulman S, Ravinder. Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. Front Immunol 2021;12:716361. [PMID: 34491250 DOI: 10.3389/fimmu.2021.716361] [Reference Citation Analysis]
21 Lim EHT, van Amstel RBE, de Boer VV, van Vught LA, de Bruin S, Brouwer MC, Vlaar APJ, van de Beek D. Complement activation in COVID-19 and targeted therapeutic options: A scoping review. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100995] [Reference Citation Analysis]
22 Barcellini W, Giannotta JA, Fattizzo B. Are Patients With Autoimmune Cytopenias at Higher Risk of COVID-19 Pneumonia? The Experience of a Reference Center in Northern Italy and Review of the Literature. Front Immunol 2020;11:609198. [PMID: 33574816 DOI: 10.3389/fimmu.2020.609198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
23 Gaikwad H, Li Y, Wang G, Li R, Dai S, Rester C, Kedl R, Saba L, Banda NK, Scheinman RI, Patrick C, Mallela KMG, Moghimi SM, Simberg D. Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on "Pseudovirus-like" Nanoparticles. ACS Nano 2022. [PMID: 35507641 DOI: 10.1021/acsnano.2c02794] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Stenmark KR, Frid MG, Gerasimovskaya E, Zhang H, McCarthy MK, Thurman JM, Morrison TE. Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement. Pulm Circ 2021;11:20458940211015799. [PMID: 34046161 DOI: 10.1177/20458940211015799] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
25 Koma T, Adachi S, Doi N, Adachi A, Nomaguchi M. Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. Front Microbiol 2020;11:2016. [PMID: 32983025 DOI: 10.3389/fmicb.2020.02016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
26 Soffin EM, Reisener MJ, Padgett DE, Kelly BT, Sama AA, Zhu J, Salzmann SN, Chiapparelli E, Okano I, Oezel L, Miller AO, Cammisa FP, Girardi FP, Hughes AP. Coronavirus Disease 2019 Exposure in Surgeons and Anesthesiologists at a New York City Specialty Hospital: A Cross-Sectional Study of Symptoms and SARS-CoV-2 Antibody Status. J Occup Environ Med 2021;63:521-7. [PMID: 34048384 DOI: 10.1097/JOM.0000000000002182] [Reference Citation Analysis]
27 Mencarini P, Scarabello A, Del Nonno F, Lalle E, Falasca L, Gualano G, Nardacci R, Mosti S, Musso M, Libertone R, Di Bari V, Rosati S, Colombo D, Castilletti C, Palmieri F. Dermatological manifestations during COVID-19 and histological picture: Description of two clinical cases. J Dermatol 2021;48:651-6. [PMID: 33624293 DOI: 10.1111/1346-8138.15714] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kozma GT, Mészáros T, Bakos T, Hennies M, Bencze D, Uzonyi B, Győrffy B, Cedrone E, Dobrovolskaia MA, Józsi M, Szebeni J. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. Front Immunol 2021;12:642860. [PMID: 33995361 DOI: 10.3389/fimmu.2021.642860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Magro CM, Mulvey J, Kubiak J, Mikhail S, Suster D, Crowson AN, Laurence J, Nuovo G. Severe COVID-19: A multifaceted viral vasculopathy syndrome. Ann Diagn Pathol 2021;50:151645. [PMID: 33248385 DOI: 10.1016/j.anndiagpath.2020.151645] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
30 Tsiftsoglou SA. SARS-CoV-2 associated Complement genetic variants possibly deregulate the activation of the Alternative pathway affecting the severity of infection. Mol Immunol 2021;135:421-5. [PMID: 33838929 DOI: 10.1016/j.molimm.2021.03.021] [Reference Citation Analysis]
31 Li Q, Chen Z. An update: the emerging evidence of complement involvement in COVID-19. Med Microbiol Immunol. 2021;1-9. [PMID: 33811541 DOI: 10.1007/s00430-021-00704-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Napolitano F, Di Spigna G, Vargas M, Iacovazzo C, Pinchera B, Spalletti Cernia D, Ricciardone M, Covelli B, Servillo G, Gentile I, Postiglione L, Montuori N. Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients. J Clin Med 2021;10:4914. [PMID: 34768433 DOI: 10.3390/jcm10214914] [Reference Citation Analysis]
33 Valentini P, Sodero G, Buonsenso D. The Relationship between COVID-19 and Innate Immunity in Children: A Review. Children (Basel) 2021;8:266. [PMID: 33808490 DOI: 10.3390/children8040266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Gusev E, Sarapultsev A, Solomatina L, Chereshnev V. SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19. Int J Mol Sci 2022;23:1716. [PMID: 35163638 DOI: 10.3390/ijms23031716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
35 De Sanctis JB, García AH, Moreno D, Hajduch M. Coronavirus infection: An immunologists' perspective. Scand J Immunol 2021;93:e13043. [PMID: 33783027 DOI: 10.1111/sji.13043] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
36 Kircheis R. Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. Int J Mol Sci 2021;22:10791. [PMID: 34639132 DOI: 10.3390/ijms221910791] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Pellegrini D, Kawakami R, Guagliumi G, Sakamoto A, Kawai K, Gianatti A, Nasr A, Kutys R, Guo L, Cornelissen A, Faggi L, Mori M, Sato Y, Pescetelli I, Brivio M, Romero M, Virmani R, Finn AV. Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. Circulation 2021;143:1031-42. [PMID: 33480806 DOI: 10.1161/CIRCULATIONAHA.120.051828] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 39.0] [Reference Citation Analysis]
38 Dong X, Wang C, Liu X, Gao W, Bai X, Li Z. Lessons Learned Comparing Immune System Alterations of Bacterial Sepsis and SARS-CoV-2 Sepsis. Front Immunol 2020;11:598404. [PMID: 33329592 DOI: 10.3389/fimmu.2020.598404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Jiang H, Chen Q, Zheng S, Guo C, Luo J, Wang H, Zheng X, Weng Z. Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19. IJGM 2022;Volume 15:849-57. [DOI: 10.2147/ijgm.s348519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Rizza S, Nucera A, Chiocchi M, Bellia A, Mereu D, Ferrazza G, Ballanti M, Davato F, Di Cola G, Buonomo CO, Coppeta L, Vanni G, Gervasi R, Cardellini M, Lauro D, Federici M. Metabolic characteristics in patients with COVID-19 and no-COVID-19 interstitial pneumonia with mild-to-moderate symptoms and similar radiological severity. Nutr Metab Cardiovasc Dis 2021;31:3227-35. [PMID: 34629249 DOI: 10.1016/j.numecd.2021.08.035] [Reference Citation Analysis]
41 Gatti E, Piotto M, Lelii M, Pensabene M, Madini B, Cerrato L, Hassan V, Aliberti S, Bosis S, Marchisio P, Patria MF. Therapeutic Strategies for COVID-19 Lung Disease in Children. Front Pediatr 2022;10:829521. [DOI: 10.3389/fped.2022.829521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T, Gäbel C, Schneider M, Streitz M, Demichev V, Gemünd I, Barone M, Tober-Lau P, Helbig ET, Hillus D, Petrov L, Stein J, Dey HP, Paclik D, Iwert C, Mülleder M, Aulakh SK, Djudjaj S, Bülow RD, Mei HE, Schulz AR, Thiel A, Hippenstiel S, Saliba AE, Eils R, Lehmann I, Mall MA, Stricker S, Röhmel J, Corman VM, Beule D, Wyler E, Landthaler M, Obermayer B, von Stillfried S, Boor P, Demir M, Wesselmann H, Suttorp N, Uhrig A, Müller-Redetzky H, Nattermann J, Kuebler WM, Meisel C, Ralser M, Schultze JL, Aschenbrenner AC, Thibeault C, Kurth F, Sander LE, Blüthgen N, Sawitzki B; PA-COVID-19 Study Group. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell 2022;185:493-512.e25. [PMID: 35032429 DOI: 10.1016/j.cell.2021.12.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
43 Mannes M, Schmidt CQ, Nilsson B, Ekdahl KN, Huber-Lang M. Complement as driver of systemic inflammation and organ failure in trauma, burn, and sepsis. Semin Immunopathol 2021. [PMID: 34191093 DOI: 10.1007/s00281-021-00872-x] [Reference Citation Analysis]
44 Kircheis R, Schuster M, Planz O. COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF-κB Pathway. Viruses 2021;13:1887. [PMID: 34578468 DOI: 10.3390/v13091887] [Reference Citation Analysis]
45 Deravi N, Ahsan E, Fathi M, Hosseini P, Yaghoobpoor S, Lotfi R, Pourbagheri-Sigaroodi A, Bashash D. Complement inhibition: A possible therapeutic approach in the fight against Covid-19. Rev Med Virol 2021;:e2316. [PMID: 34873779 DOI: 10.1002/rmv.2316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Lynch NJ, Chan ACY, Ali YM, Khatri P, Bamigbola IE, Demopulos G, Paganessi M, Rambaldi A, Schwaeble WJ. Inhibition of the lectin pathway of complement ameliorates hypocomplementemia and restores serum bactericidal activity in patients with severe COVID-19. Clin Transl Med 2022;12:e980. [PMID: 35839316 DOI: 10.1002/ctm2.980] [Reference Citation Analysis]
47 Moulana Z, Bagherzadeh M, Mirzakhani M, Rostami A, Mohammadnia-Afrouzi M, Shahbazi M. Increased Levels of serum Pentraxin 3 in Critical Coronavirus Disease-2019 Patients. Environ Sci Pollut Res Int 2021. [PMID: 34212320 DOI: 10.1007/s11356-021-15183-9] [Reference Citation Analysis]
48 Macor P, Durigutto P, Mangogna A, Bussani R, D'Errico S, Zanon M, Pozzi N, Meroni P, Tedesco F. Multi-organ complement deposition in COVID-19 patients. medRxiv 2021:2021. [PMID: 33442701 DOI: 10.1101/2021.01.07.21249116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
49 Ortiz A. Complement and protection from tissue injury in COVID-19. Clin Kidney J 2020;13:734-8. [PMID: 33123353 DOI: 10.1093/ckj/sfaa196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Santos NB, Vaz da Silva ZE, Gomes C, Reis CA, Amorim MJ. Complement Decay-Accelerating Factor is a modulator of influenza A virus lung immunopathology. PLoS Pathog 2021;17:e1009381. [PMID: 34197564 DOI: 10.1371/journal.ppat.1009381] [Reference Citation Analysis]
51 Świerzko AS, Cedzyński M. The Influence of the Lectin Pathway of Complement Activation on Infections of the Respiratory System. Front Immunol 2020;11:585243. [PMID: 33193407 DOI: 10.3389/fimmu.2020.585243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Howell MC, Green R, McGill AR, Kahlil RM, Dutta R, Mohapatra SS, Mohapatra S. Activation of Intracellular Complement in Lungs of Patients With Severe COVID-19 Disease Decreases T-Cell Activity in the Lungs. Front Immunol 2021;12:700705. [PMID: 34899680 DOI: 10.3389/fimmu.2021.700705] [Reference Citation Analysis]
53 Jiao Y, Yang Y, Zhou L, Chen D, Lu Y. Two Natural Flavonoid Substituted Polysaccharides from Tamarix chinensis: Structural Characterization and Anticomplement Activities. Molecules 2022;27:4532. [PMID: 35889403 DOI: 10.3390/molecules27144532] [Reference Citation Analysis]
54 Haybar H, Maniati M, Saki N, Zayeri ZD. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Mol Biol Rep 2021;48:2917-28. [PMID: 33837899 DOI: 10.1007/s11033-021-06333-w] [Reference Citation Analysis]
55 Mohammed Y, Goodlett DR, Cheng MP, Vinh DC, Lee TC, Mcgeer A, Sweet D, Tran K, Lee T, Murthy S, Boyd JH, Singer J, Walley KR, Patrick DM, Quan C, Ismail S, Amar L, Pal A, Bassawon R, Fesdekjian L, Gou K, Lamontagne F, Marshall J, Haljan G, Fowler R, Winston BW, Russell JA; ARBs CORONA I. Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. J Proteome Res 2022. [PMID: 35143212 DOI: 10.1021/acs.jproteome.1c00863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
56 Alexaki VI, Henneicke H. The Role of Glucocorticoids in the Management of COVID-19. Horm Metab Res 2021;53:9-15. [PMID: 33207372 DOI: 10.1055/a-1300-2550] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
57 Macor P, Durigutto P, Mangogna A, Bussani R, De Maso L, D'Errico S, Zanon M, Pozzi N, Meroni PL, Tedesco F. Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. Biomedicines 2021;9:1003. [PMID: 34440207 DOI: 10.3390/biomedicines9081003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Attiq A, Yao LJ, Afzal S, Khan MA. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. Int Immunopharmacol 2021;101:108255. [PMID: 34688149 DOI: 10.1016/j.intimp.2021.108255] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 Lipcsey M, Persson B, Eriksson O, Blom AM, Fromell K, Hultström M, Huber-Lang M, Ekdahl KN, Frithiof R, Nilsson B. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. Front Immunol 2021;12:627579. [PMID: 33692801 DOI: 10.3389/fimmu.2021.627579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
60 Gutmann C, Takov K, Burnap SA, Singh B, Ali H, Theofilatos K, Reed E, Hasman M, Nabeebaccus A, Fish M, McPhail MJ, O'Gallagher K, Schmidt LE, Cassel C, Rienks M, Yin X, Auzinger G, Napoli S, Mujib SF, Trovato F, Sanderson B, Merrick B, Niazi U, Saqi M, Dimitrakopoulou K, Fernández-Leiro R, Braun S, Kronstein-Wiedemann R, Doores KJ, Edgeworth JD, Shah AM, Bornstein SR, Tonn T, Hayday AC, Giacca M, Shankar-Hari M, Mayr M. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat Commun 2021;12:3406. [PMID: 34099652 DOI: 10.1038/s41467-021-23494-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
61 Bojkova D, Bechtel M, McLaughlin KM, McGreig JE, Klann K, Bellinghausen C, Rohde G, Jonigk D, Braubach P, Ciesek S, Münch C, Wass MN, Michaelis M, Cinatl J Jr. Aprotinin Inhibits SARS-CoV-2 Replication. Cells 2020;9:E2377. [PMID: 33143316 DOI: 10.3390/cells9112377] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
62 Matera MG, Rogliani P, Calzetta L, Cazzola M. Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respir Med 2020;171:106114. [PMID: 32795902 DOI: 10.1016/j.rmed.2020.106114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]